Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 20/20 | 0.57 |
| ▸ | GABRG2 | P18507 | 20/20 | 0.57 |
| ▸ | GABRB3 | P28472 | 20/20 | 0.57 |
| ▸ | GABRA2 | P47869 | 11/20 | 0.57 |
| ▸ | GABRA3 | P34903 | 16/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 14/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6200597 | 0.84 | GABRA1 (0.61) | GABRA1GABRG2GABRB3GABRA2GABRA3 | |
| SCHEMBL5259781 | 0.82 | GABRA1 (0.62) | GABRA1GABRG2GABRB3GABRA2GABRA3 | |
| SCHEMBL5261634 | 0.82 | GABRA1 (0.60) | GABRA1GABRG2GABRB3GABRA2GABRA3 | |
| SCHEMBL6202804 | 0.80 | GABRA1 (0.47) | GABRA1GABRG2GABRB3GABRA2GABRA3 | |
| SCHEMBL6200800 | 0.80 | GABRA1 (0.72) | GABRA1GABRG2GABRB3GABRA2GABRA3 | |
| SCHEMBL6201330 | 0.80 | GABRA1 (0.48) | GABRA1GABRG2GABRB3GABRA2GABRA3 | |
| SCHEMBL5264102 | 0.80 | GABRA1 (0.55) | GABRA1GABRG2GABRB3GABRA2GABRA3 | |
| SCHEMBL5262785 | 0.79 | GABRA1 (0.57) | GABRA1GABRG2GABRB3GABRA2GABRA3 | |
| SCHEMBL6201868 | 0.78 | GABRA1 (0.66) | GABRA1GABRG2GABRB3GABRA2GABRA3 | |
| SCHEMBL6201629 | 0.78 | GABRA1 (0.78) | GABRA1GABRG2GABRB3GABRA2GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451161-B1 | IMIDAZOPYRIDINES, PYRIMIDINES AND TRIAZINES FOR ENHANCING COGNITION AS GABA-A ALPHA 5 RECEPTOR SUBTYPE LIGANDS | MERCK SHARP & DOHME (GB) | 2007-04-18 | — | — | EP | claimed |
| US-20060040940-A1 | Imidazopyridines pyrimidines and triazines for enhancing cognition as gaba-a-alphas 5 receoptor subtype ligands | BETTATI MICHELA | 2006-02-23 | — | — | US | claimed |
| EP-1451161-B1 | IMIDAZOPYRIDINES, PYRIMIDINES AND TRIAZINES FOR ENHANCING COGNITION AS GABA-A ALPHA 5 RECEPTOR SUBTYPE LIGANDS | MERCK SHARP & DOHME (GB) | 2007-04-18 | — | — | EP | disclosed |
| US-20060040940-A1 | Imidazopyridines pyrimidines and triazines for enhancing cognition as gaba-a-alphas 5 receoptor subtype ligands | BETTATI MICHELA | 2006-02-23 | — | — | US | disclosed |
| EP-1451161-A1 | IMIDAZOPYRIDINES, PYRIMIDINES AND TRIAZINES FOR ENHANCING COGNITION AS GABA-A ALPHA 5 RECEPTOR SUBTYPE LIGANDS | Merck Sharp & Dohme Limited (GB) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003048132-A1 | IMIDAZOPYRIDINES, PYRIMIDINES AND TRIAZINES FOR ENHANCING COGNITION AS GABA-A ALPHA 5 RECEPTOR SUBTYPE LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040940-A1 | Imidazopyridines pyrimidines and triazines for enhancing cognition as gaba-a-alphas 5 receoptor subtype ligands | CHRNA3, GABRA3, GABRB3 | GABRA1 8/4885GABRG2 61/4885GABRB3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.